Medicamen Organics Ltd

Medicamen Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Medicamen Organics Ltd

₹ 29.0 4.89%
17 Apr - close price
Company website NSE - SME: MEDIORG
About

Incorporated in 1995, Medicamen Organics Ltd develops, manufactures, and distributes a broad range of pharmaceutical dosages including generic dosage[1]

Key Points

Business Overview:[1][2]
MOL specializes in manufacturing and distributing tablets, capsules, syrups, and ointments. It offers B2B contract and third-party manufacturing services for pharma companies in India and globally. Its portfolio includes generic and branded formulations, catering to government sectors, private institutions, and prominent pharma firms. Products are marketed via third-party distributors and loan licensing agreements.

Website NSE - ST
  • Market Cap ₹ 33.9 Cr.
  • Current Price ₹ 29.0
  • High / Low ₹ 159 / 19.6
  • Stock P/E 14.1
  • Book Value ₹ 23.3
  • Dividend Yield 0.00 %
  • ROCE 16.6 %
  • ROE 19.9 %
  • Face Value ₹ 10.0
Edit ratios

Pros

Cons

  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has a low return on equity of 12.4% over last 3 years.
  • Company might be capitalizing the interest cost
  • Company has high debtors of 241 days.
  • Working capital days have increased from 179 days to 252 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations

Edit Columns
Loading peers table ...

Half Yearly Results

Figures in Rs. Crores

Sep 2023 Sep 2024
11.32 16.61
8.91 14.09
Operating Profit 2.41 2.52
OPM % 21.29% 15.17%
1.05 0.25
Interest 0.29 0.22
Depreciation 0.36 0.36
Profit before tax 2.81 2.19
Tax % 51.96% 30.59%
1.36 1.51
EPS in Rs 1.70 1.29
Raw PDF

Profit & Loss

Figures in Rs. Crores

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
31.49 25.05 20.98 22.15 25.27
30.14 23.41 19.78 20.29 20.53
Operating Profit 1.35 1.64 1.20 1.86 4.74
OPM % 4.29% 6.55% 5.72% 8.40% 18.76%
0.09 0.01 0.21 0.82 0.02
Interest 0.46 0.48 0.47 0.61 0.65
Depreciation 0.77 0.68 0.68 0.71 0.72
Profit before tax 0.21 0.49 0.26 1.36 3.39
Tax % 47.62% 40.82% 61.54% 28.68% 28.91%
0.10 0.30 0.09 0.97 2.40
EPS in Rs 0.17 0.50 0.15 1.62 2.79
Dividend Payout % 0.00% 0.00% 0.00% 0.00% 0.00%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: 0%
TTM: 14%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: 100%
TTM: 147%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: %
Return on Equity
10 Years: %
5 Years: %
3 Years: 12%
Last Year: 20%

Balance Sheet

Figures in Rs. Crores

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2024
Equity Capital 6.00 6.00 6.00 6.00 8.60 11.70
Reserves 1.11 1.47 1.56 2.98 6.58 15.61
8.27 9.59 10.24 11.79 12.66 12.88
10.44 9.28 9.27 11.82 10.75 8.80
Total Liabilities 25.82 26.34 27.07 32.59 38.59 48.99
11.28 11.35 11.29 10.87 10.35 10.39
CWIP 0.06 0.00 0.00 0.00 0.15 0.15
Investments 0.00 0.00 0.00 0.00 0.00 0.00
14.48 14.99 15.78 21.72 28.09 38.45
Total Assets 25.82 26.34 27.07 32.59 38.59 48.99

Cash Flows

Figures in Rs. Crores

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
1.58 -1.16 0.04 -0.58 -3.69
-0.45 -0.02 -0.59 -0.28 -0.33
-0.55 1.27 0.18 0.94 4.01
Net Cash Flow 0.58 0.09 -0.37 0.07 -0.01

Ratios

Figures in Rs. Crores

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 63.98 109.72 108.73 177.47 241.21
Inventory Days 101.47 61.22 128.47 225.01 244.39
Days Payable 225.45 161.56 198.97 329.82 281.81
Cash Conversion Cycle -60.01 9.38 38.24 72.66 203.80
Working Capital Days 34.66 83.35 121.61 163.30 251.61
ROCE % 5.98% 4.19% 10.22% 16.62%

Shareholding Pattern

Numbers in percentages

Sep 2024Mar 2025
59.69% 59.73%
0.14% 0.07%
3.76% 3.79%
36.41% 36.41%
No. of Shareholders 379460

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Concalls